VEEV Veeva Systems
An excellent life-sciences cloud franchise, but the price already discounts a flawless decade of compounding.
The story
Veeva is the system of record for life-sciences commercial and R&D workflows. Its moat comes from high switching costs, regulatory-grade data, and deep pharma relationships. The company is in late high-growth: the Vault platform keeps compounding, while the Salesforce-to-Vault CRM migration and competition from IQVIA and Salesforce cap upside in the commercial suite. TTM revenue of $3.46B at a 29.9% GAAP margin confirms durable operating leverage, but growth is drifting from the mid-teens toward low double digits.
I kept most of the previous drivers because the story has not changed. GAAP margin rose again, from 28.7% to 29.9%, so the target moves from 37% to 39%. That is about a 5% relative change, not a material move: non-GAAP margins already sit in the low 40s, and stock-based compensation explains the gap. Sales-to-capital edges up to 1.9 because the reported 0.48 is distorted by excess cash, and the asset-light Vault expansion needs little capital. A 12-year horizon fits a regulated-workflow franchise with a long R&D cloud runway. Even so, the market price still implies near-flawless execution well beyond these drivers.
Value drivers
| Revenue growth (Y1) | 13.0% |
| Terminal growth | 4.0% |
| Forecast horizon | 12y |
| Target operating margin | 39.0% |
| Years to target margin | 6 |
| Sales-to-capital | 1.90 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 8.8% |
Valuation bridge
| PV of explicit FCFF | 10.89B |
| PV of terminal value | 13.91B |
| Equity value | 25.70B |
| ÷ shares → per share | $158.76 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.91B | 13.0% | 31.4% | 934.76M | 236.61M | 698.16M | 643.02M |
| 2 | 4.38B | 12.2% | 33.0% | 1.10B | 250.54M | 848.54M | 719.80M |
| 3 | 4.88B | 11.4% | 34.5% | 1.28B | 262.18M | 1.02B | 795.33M |
| 4 | 5.40B | 10.5% | 36.0% | 1.48B | 270.95M | 1.21B | 868.04M |
| 5 | 5.92B | 9.7% | 37.5% | 1.69B | 276.29M | 1.41B | 936.34M |
| 6 | 6.45B | 8.9% | 39.0% | 1.91B | 277.66M | 1.64B | 998.71M |
| 7 | 6.97B | 8.1% | 39.0% | 2.07B | 274.63M | 1.79B | 1.01B |
| 8 | 7.48B | 7.3% | 39.0% | 2.22B | 266.83M | 1.95B | 1.01B |
| 9 | 7.96B | 6.5% | 39.0% | 2.36B | 254.03M | 2.11B | 1.01B |
| 10 | 8.41B | 5.6% | 39.0% | 2.50B | 236.15M | 2.26B | 992.38M |
| 11 | 8.81B | 4.8% | 39.0% | 2.62B | 213.25M | 2.40B | 971.91M |
| 12 | 9.17B | 4.0% | 39.0% | 2.72B | 185.57M | 2.53B | 944.45M |
Key risks
- CRM share loss or price pressure from Salesforce Life Sciences Cloud and IQVIA during the Vault CRM migration
- Pharma budget cuts, consolidation, and drug-pricing pressure (IRA, MFN) slowing seat and module growth
- Growth decelerating to high single digits sooner than expected, compressing the premium multiple
Catalysts
- Top-20 pharma Vault CRM go-lives and clinical platform wins that show growth can be sustained
- Continued GAAP margin expansion plus buybacks funded from a large net-cash position